Real-World Data From a Molecular Tumor Board-Assisted Cancer
Care From a Single Center in The Czech Republic: Is Precision
Oncology an Accessible Option, or a Privilege for a Minority of
Patients?

ENPřihlásit se Přihlásit se (EduID)

Real-World Data From a Molecular Tumor Board-Assisted Cancer Care From a Single Center in The Czech ...

Přehled o publikaci

J 2025

Real-World Data From a Molecular Tumor Board-Assisted Cancer Care From a Single Center in The Czech Republic: Is Precision Oncology an Accessible Option, or a Privilege for a Minority of Patients?

EID, Michal; Markéta BEDNAŘÍKOVÁ; Jakub VLAŽNÝ; Jitka HAUSNEROVÁ; Renata TASLEROVÁ et. al.

Základní údaje

Originální název

Real-World Data From a Molecular Tumor Board-Assisted Cancer Care From a Single Center in The Czech Republic: Is Precision Oncology an Accessible Option, or a Privilege for a Minority of Patients?

Autoři

Vydání

Cancer Medicine, Hoboken, Sons Ltd. 2025, 2045-7634

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Organizace

Lékařská fakulta – Masarykova univerzita – Repozitář

DOI

https://doi.org/10.1002/cam4.71119

UT WoS

001543062700001

EID Scopus

2-s2.0-105012466693

Klíčová slova anglicky

biomarkers; cancer genetics; next-generation sequencing; target therapy

Návaznosti

LM2018132, projekt VaV. LX22NPO5102, projekt VaV. MUNI/A/1685/2024, interní kód Repo. CZECRIN IV, velká výzkumná infrastruktura.

Změněno: 15. 10. 2025 00:51, RNDr. Daniel Jakubík

Anotace

V originále

gt;= 1.3 was observed in 29 (41.4%) of the 70 evaluable pretreated patients.ConclusionThis is the first study to report on a real-world MTB cohort from the Czech Republic, demonstrating a diagnostic yield comparable to previously published studies, good availability of recommended drugs, and clinical benefit in evaluable patients.

Přiložené soubory

https://is.muni.cz/publication/2521262/Real-World_Data_From_a_Molecular_Tumor_Board-Assisted_Cancer_Care_From_a_Single_Center_in_The_Czech_Republic_Is_Precision_Oncology_an_Accessible_Option__or_a_Privilege_for_a_Minority_of_Patients.pdf

Citovat

EID, Michal; Markéta BEDNAŘÍKOVÁ; Jakub VLAŽNÝ; Jitka HAUSNEROVÁ; Renata TASLEROVÁ; Sára VILMANOVÁ; Martina JELÍNKOVÁ; Alena HOMOLOVÁ; Martin GRYC; Jakub TRIZULJAK; Zdeněk PAVLOVSKÝ; Štěpán TUČEK; Dagmar BRANČÍKOVÁ; Monika BRATOVÁ; Tomáš ROHAN; Zdeněk KALA; Zdeněk KRÁL; Jiří MAYER; Adam SVOBODNÍK a Ondřej SLABÝ. Real-World Data From a Molecular Tumor Board-Assisted Cancer Care From a Single Center in The Czech Republic: Is Precision Oncology an Accessible Option, or a Privilege for a Minority of Patients? Cancer Medicine. Hoboken: Sons Ltd., 2025, roč. 14, č. 15, s. 1-12. ISSN 2045-7634. Dostupné z: https://doi.org/10.1002/cam4.71119.

@article{84494,
   author = {Eid, Michal and Bednaříková, Markéta and Vlažný, Jakub and Hausnerová, Jitka and Taslerová, Renata and Vilmanová, Sára and Jelínková, Martina and Homolová, Alena and Gryc, Martin and Trizuljak, Jakub and Pavlovský, Zdeněk and Tuček, Štěpán and Brančíková, Dagmar and Bratová, Monika and Rohan, Tomáš and Kala, Zdeněk and Král, Zdeněk and Mayer, Jiří and Svobodník, Adam and Slabý, Ondřej},
   article_location = {Hoboken},
   article_number = {15},
   doi = {https://doi.org/10.1002/cam4.71119},
   keywords = {biomarkers; cancer genetics; next-generation sequencing; target therapy},
   language = {eng},
   issn = {2045-7634},
   journal = {Cancer Medicine},
   title = {Real-World Data From a Molecular Tumor Board-Assisted Cancer Care From a Single Center in The Czech Republic: Is Precision Oncology an Accessible Option, or a Privilege for a Minority of Patients?},
   url = {https://onlinelibrary.wiley.com/doi/10.1002/cam4.71119},
   volume = {14},
   year = {2025}
}

TY  - JOUR
ID  - 84494
AU  - Eid, Michal - Bednaříková, Markéta - Vlažný, Jakub - Hausnerová, Jitka - Taslerová, Renata - Vilmanová, Sára - Jelínková, Martina - Homolová, Alena - Gryc, Martin - Trizuljak, Jakub - Pavlovský, Zdeněk - Tuček, Štěpán - Brančíková, Dagmar - Bratová, Monika - Rohan, Tomáš - Kala, Zdeněk - Král, Zdeněk - Mayer, Jiří - Svobodník, Adam - Slabý, Ondřej
PY  - 2025
TI  - Real-World Data From a Molecular Tumor Board-Assisted Cancer Care From a Single Center in The Czech Republic: Is Precision Oncology an Accessible Option, or a Privilege for a Minority of Patients?
JF  - Cancer Medicine
VL  - 14
IS  - 15
SP  - 1-12
EP  - 1-12
PB  - Sons Ltd.
SN  - 2045-7634
KW  - biomarkers
KW  - cancer genetics
KW  - next-generation sequencing
KW  - target therapy
UR  - https://onlinelibrary.wiley.com/doi/10.1002/cam4.71119
N2  - gt;= 1.3 was observed in 29 (41.4%) of the 70 evaluable pretreated patients.ConclusionThis is the first study to report on a real-world MTB cohort from the Czech Republic, demonstrating a diagnostic yield comparable to previously published studies, good availability of recommended drugs, and clinical benefit in evaluable patients.
ER  -

EID, Michal; Markéta BEDNAŘÍKOVÁ; Jakub VLAŽNÝ; Jitka HAUSNEROVÁ; Renata TASLEROVÁ; Sára VILMANOVÁ; Martina JELÍNKOVÁ; Alena HOMOLOVÁ; Martin GRYC; Jakub TRIZULJAK; Zdeněk PAVLOVSKÝ; Štěpán TUČEK; Dagmar BRANČÍKOVÁ; Monika BRATOVÁ; Tomáš ROHAN; Zdeněk KALA; Zdeněk KRÁL; Jiří MAYER; Adam SVOBODNÍK a Ondřej SLABÝ. Real-World Data From a Molecular Tumor Board-Assisted Cancer Care From a Single Center in The Czech Republic: Is Precision Oncology an Accessible Option, or a Privilege for a Minority of Patients? \textit{Cancer Medicine}. Hoboken: Sons Ltd., 2025, roč.~14, č.~15, s.~1-12. ISSN~2045-7634. Dostupné z: https://doi.org/10.1002/cam4.71119.